Arsenic sulfide nanoformulation induces erythroid differentiation in chronic myeloid leukemia cells through degradation of BCR-ABL

References

• Faderl S, Talpaz M, Estrov Z, O’Brien S, Kurzrock R, Kantarjian HM. Mechanisms of disease - the biology of chronic myeloid leukemia. New Engl J Med. 1999;341(3):164–172. doi:10.1056/NEJM19990715341030610403855
   PubMed Web of Science ®Google Scholar
• Pierce A, Spooncer E, Ainsworth S, Whetton AD. BCR-ABL alters the proliferation and differentiation response of multipotent hematopoietic cells to stem cell factor. Oncogene. 2002;21(19):3068–3075. doi:10.1038/sj.onc.120542412082538
   PubMedGoogle Scholar
• Fang GF, Kim CN, Perkins CL, et al. CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs. Blood. 2000;96(6):2246–2253.10979973
   PubMed Web of Science ®Google Scholar
• Jacquel A, Colosetti P, Grosso S, et al. Apoptosis and erythroid differentiation triggered by Bcr-Abl inhibitors in CML cell lines are fully distinguishable processes that exhibit different sensitivity to caspase inhibition. Oncogene. 2007;26(17):2445–2458. doi:10.1038/sj.onc.121003417043649
   PubMedGoogle Scholar
• Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. New Engl J Med. 2006;355(23):2408–2417. doi:10.1056/NEJMoa06286717151364
   PubMed Web of Science ®Google Scholar
• O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. New Engl J Med. 2003;348(11):994–1004. doi:10.1056/NEJMoa02245712637609
   PubMed Web of Science ®Google Scholar
• Hochhaus A, Larson RA, Guilhot F, et al. Long-term outcomes of imatinib treatment for chronic myeloid leukemia. N Engl J Med. 2017;376(10):917–927. doi:10.1056/NEJMoa160932428273028
   PubMed Web of Science ®Google Scholar
• O’Hare T, Zabriskie MS, Eiring AM, Deininger MW. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer. 2012;12(8):513–526. doi:10.1038/nrc331722825216
   PubMed Web of Science ®Google Scholar
• Tong Y, Wu YL, Sun HP, et al. Combined effects of As4S4 and imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood. 2004;104(13):4219–4225. doi:10.1182/blood-2004-04-143315339852
   PubMedGoogle Scholar
• Lu DP, Qiu JY, Jiang B, et al. Tetra-arsenic tetra-sulfide for the treatment of acute promyelocytic leukemia: a pilot report. Blood. 2002;99(9):3136–3143. doi:10.1182/blood.v99.9.313611964275
   PubMed Web of Science ®Google Scholar
• Zhu HH, Huang XJ, Arsenic O. Retinoic acid for non-high-risk acute promyelocytic leukemia. New Engl J Med. 2014;371(23):2239–2241. doi:10.1056/NEJMc1412035
   PubMed Web of Science ®Google Scholar
• Zhu HH, Liu YR, Jia JS, Qin YZ, Zhao XS, Lai YY. Oral arsenic and all-trans retinoic acid for high-risk acute promyelocytic leukemia. Blood. 2018;131(26):2987–2989. doi:10.1182/blood-2018-02-83405129728404
   PubMed Web of Science ®Google Scholar
• Zhu HH, Wu DP, Du X, et al. Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial. Lancet Oncol. 2018;19(7):871–879. doi:10.1016/S1470-2045(18)30295-X29884593
   PubMed Web of Science ®Google Scholar
• Kwan SY, Tsui SK, Man TO. Release of soluble arsenic from Realgar in simulated gastric juice. Anal Lett. 2001;34(9):1431–1436. doi:10.1081/AL-100104917
   Web of Science ®Google Scholar
• Ma Q, Wang C, Li X, et al. Fabrication of water-soluble polymer-encapsulated As4S4 to increase oral bioavailability and chemotherapeutic efficacy in AML mice. Sci Rep. 2016;6:29348. doi:10.1038/srep2934827383126
   PubMedGoogle Scholar
• Mao JH, Sun XY, Liu JX, et al. As4S4 targets RING-type E3 ligase c-CBL to induce degradation of BCR-ABL in chronic myelogenous leukemia. P Natl Acad Sci USA. 2010;107(50):21683–21688. doi:10.1073/pnas.1016311108
   PubMed Web of Science ®Google Scholar
• Huang YW, Lee WH, Tsai YH, Huang HM. Activin A induction of erythroid differentiation sensitizes K562 chronic myeloid leukemia cells to a subtoxic concentration of imatinib. Am J Physiol Cell Physiol. 2014;306(1):C37–C44. doi:10.1152/ajpcell.00130.201324088895
   PubMedGoogle Scholar
• Lee YL, Chen CW, Liu FH, Huang YW, Huang HM. Aclacinomycin A sensitizes K562 chronic myeloid leukemia cells to imatinib through p38MAPK-mediated erythroid differentiation. PLoS One. 2013;8(4):e61939. doi:10.1371/journal.pone.006193923613979
   PubMedGoogle Scholar
• Goussetis DJ, Gounaris E, Wu EJ, et al. Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. Blood. 2012;120(17):3555–3562. doi:10.1182/blood-2012-01-40257822898604
   PubMed Web of Science ®Google Scholar
• White E, Mehnert JM, Chan CS. Autophagy, metabolism, and cancer. Clin Cancer Res. 2015;21(22):5037–5046. doi:10.1158/1078-0432.CCR-15-049026567363
   PubMed Web of Science ®Google Scholar
• Cao Y, Fang YX, Cai JY, et al. ROS functions as an upstream trigger for autophagy to drive hematopoietic stem cell differentiation. Hematology. 2016;21(10):613–618. doi:10.1080/10245332.2016.116544627077779
   PubMed Web of Science ®Google Scholar
• Liang Q, Wang XP, Chen TS. Resveratrol protects rabbit articular chondrocyte against sodium nitroprusside-induced apoptosis via scavenging ROS. Apoptosis. 2014;19(9):1354–1363. doi:10.1007/s10495-014-1012-125001340
   PubMedGoogle Scholar
• Moosavi MA, Sharifi M, Ghafary SM, et al. Photodynamic N-TiO2 nanoparticle treatment induces controlled ros-mediated autophagy and terminal differentiation of leukemia cells. Sci Rep. 2016;6:34413.
   Web of Science ®Google Scholar
• Chen YF, Liu H, Luo XJ, et al. The roles of reactive oxygen species (ROS) and autophagy in the survival and death of leukemia cells. Crit Rev Oncol Hemat. 2017;112:21–30. doi:10.1016/j.critrevonc.2017.02.004
   PubMed Web of Science ®Google Scholar
• Irwin ME, Rivera-Del Valle N, Chandra J. Redox control of leukemia: from molecular mechanisms to therapeutic opportunities. Antioxid Redox Sign. 2013;18(11):1349–1383. doi:10.1089/ars.2011.4258
   PubMed Web of Science ®Google Scholar
• Sattler M, Verma S, Shrikhande G, et al. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem. 2000;275(32):24273–24278. doi:10.1074/jbc.M00209420010833515
   PubMedGoogle Scholar
• Chandel NS, McClintock DS, Feliciano CE, et al. Reactive oxygen species generated at mitochondrial complex III stabilize hypoxia-inducible factor-1 alpha during hypoxia - A mechanism of O-2 sensing. J Biol Chem. 2000;275(33):25130–25138. doi:10.1074/jbc.M00191420010833514
   PubMed Web of Science ®Google Scholar
• Woo S-M, Choi YK, Kim AJ, Cho S-G, Ko S-G. p53 causes butein‑mediated apoptosis of chronic myeloid leukemia cells. Mol Med Rep. 2016;13(2):1091–1096. doi:10.3892/mmr.2015.467226676515
   PubMedGoogle Scholar
• Mazharian A, Ghevaert C, Zhang L, Massberg S, Watson SP. Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation. Blood. 2011;117(19):5198–5206. doi:10.1182/blood-2010-12-32685021385851
   PubMedGoogle Scholar
• de Thé H. Differentiation therapy revisited. Nat Rev Cancer. 2018;18(2):117–127. doi:10.1038/nrc.2017.10329192213
   PubMed Web of Science ®Google Scholar
• El Eit RM, Iskandarani AN, Saliba JL, et al. Effective targeting of chronic myeloid leukemia initiating activity with the combination of arsenic trioxide and interferon alpha. Int J Cancer. 2014;134(4):988–996. doi:10.1002/ijc.2842723934954
   PubMedGoogle Scholar
• Cholujova D, Bujnakova Z, Dutkova E, et al. Realgar nanoparticles versus ATO arsenic compounds induce in vitro and in vivo activity against multiple myeloma. Br J Haematol. 2017;179(5):756–771. doi:10.1111/bjh.1497429048129
   PubMedGoogle Scholar
• Song P, Chen P, Wang D, et al. Realgar transforming solution displays anticancer potential against human hepatocellular carcinoma HepG2 cells by inducing ROS. Int J Oncol. 2017;50(2):660–670. doi:10.3892/ijo.2016.383128035418
   PubMedGoogle Scholar
• Tian Y, Wang X, Xi R, et al. Enhanced antitumor activity of realgar mediated by milling it to nanosize. Int J Nanomedicine. 2014;9:745–757. doi:10.2147/IJN.S5639124516332
   PubMed Web of Science ®Google Scholar
• Zhao W, Lu X, Yuan Y, et al. Effect of size and processing method on the cytotoxicity of realgar nanoparticles in cancer cell lines. Int J Nanomedicine. 2011;6:1569–1577. doi:10.2147/IJN.S2137321845047
   PubMed Web of Science ®Google Scholar
• Takubo K, Goda N, Yamada W, et al. Regulation of the HIF-1 alpha Level is essential for hematopoietic stem cells. Cell Stem Cell. 2010;7(3):391–402. doi:10.1016/j.stem.2010.06.02020804974
   PubMed Web of Science ®Google Scholar